Report reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

1. Thyroid Cancer - Pipeline Review, H1 2013
Global Markets Direct’s, 'Thyroid Cancer - Pipeline Review, H1 2013', provides an overview of the
indication’s therapeutic pipeline. This report provides information on the therapeutic development for
Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It
also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer -
Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party sources, put together by Global
Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Scope
A snapshot of the global therapeutic scenario for Thyroid Cancer. A review of the Thyroid Cancer products
under development by companies and universities/research institutes based on information derived from
company and industry-specific sources. Coverage of products based on various stages of development ranging
from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and
combined therapeutics. Coverage of the Thyroid Cancer pipeline on the basis of route of administration and
molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products.
Reasons to buy
Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to
gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. Devise corrective measures for pipeline projects by understanding Thyroid Cancer
pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive projects to enhance and expand business
potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding
the factors that drove them from pipeline.
table Of Content
introduction
global Markets Direct Report Coverage
thyroid Cancer Overview
therapeutics Development
an Overview Of Pipeline Products For Thyroid Cancer
thyroid Cancer Therapeutics Under Development By Companies
thyroid Cancer Therapeutics Under Investigation By Universities/institutes
late Stage Products
Thyroid Cancer - Pipeline Review, H1 2013

2. comparative Analysis
mid Clinical Stage Products
comparative Analysis
early Clinical Stage Products
comparative Analysis
discovery And Pre-clinical Stage Products
comparative Analysis
thyroid Cancer Therapeutics – Products Under Development By Companies
thyroid Cancer Therapeutics – Products Under Investigation By Universities/institutes
companies Involved In Thyroid Cancer Therapeutics Development
bristol-myers Squibb Company
f. Hoffmann-la Roche Ltd.
biogen Idec Inc.
sanofi-aventis
astrazeneca Plc
daiichi Sankyo Company, Ltd
merck & Co., Inc.
emergent Biosolutions Inc.
takeda Pharmaceutical Company Limited
plexxikon Inc.
reliance Life Sciences Pvt. Ltd.
celltrion, Inc.
bio-path Holdings, Inc.
novartis Ag
eisai Co., Ltd.
genmab A/s
sandoz Inc.
exelixis, Inc.
celgene Corporation
bayer Ag
epicept Corporation
immunomedics, Inc
methylgene Inc
bionomics Limited
oxigene, Inc.
accentia Biopharmaceuticals, Inc.
pharmacyclics, Inc.
cancer Research Technology Limited
memgen, Llc.
azaya Therapeutics, Inc.
vascular Biogenics Ltd.
globeimmune, Inc.
biovista Inc.
Thyroid Cancer - Pipeline Review, H1 2013

3. amplimed Corporation
curetech Ltd.
genelux Corporation
trophogen, Inc.
thyroid Cancer – Therapeutics Assessment
assessment By Monotherapy Products
assessment By Route Of Administration
assessment By Molecule Type
drug Profiles
lenvatinib - Drug Profile
motesanib Diphosphate - Drug Profile
pasireotide - Drug Profile
obinutuzumab - Drug Profile
sorafenib Tosylate - Drug Profile
vandetanib - Drug Profile
vandetanib - Drug Profile
mocetinostat - Drug Profile
ibrutinib - Drug Profile
abexinostat Hydrochloride - Drug Profile
sar-245409 - Drug Profile
panobinostat - Drug Profile
dasiprotimut T - Drug Profile
docetaxel Liposomal - Drug Profile
vemurafenib - Drug Profile
cabozantinib - Drug Profile
cabozantinib - Drug Profile
isf-35 - Drug Profile
imexon - Drug Profile
vb-111 - Drug Profile
bms-936564 - Drug Profile
pidilizumab - Drug Profile
bp-100-1.02 - Drug Profile
trx-201 - Drug Profile
autologous Recombinant Idiotypic Vaccine - Drug Profile
gi-6207 - Drug Profile
epratuzumab - Drug Profile
plx-3397 - Drug Profile
buparlisib - Drug Profile
lithium Carbonate - Drug Profile
lenalidomide - Drug Profile
di-leu16-il2 Immunocytokine - Drug Profile
ofatumumab - Drug Profile
fosbretabulin Disodium - Drug Profile
Thyroid Cancer - Pipeline Review, H1 2013

4. rituximab - Drug Profile
ocaratuzumab - Drug Profile
rituximab Biosimilar - Drug Profile
rituximab Biosimilar - Drug Profile
etd-5 - Drug Profile
abt-199 - Drug Profile
rituximab Biosimilar - Drug Profile
thyroid Stimulating Hormone Analog - Drug Profile
rituximab Biosimilar - Drug Profile
plx-4720 - Drug Profile
131i-rituximab - Drug Profile
drug Adaptation Program - Drug Profile
edc-1 - Drug Profile
andrographolide - Drug Profile
interferon Alfa-2b Biosimilar - Drug Profile
drug For Lung And Thyroid Cancer - Drug Profile
glonc-2 - Drug Profile
bva-501 - Drug Profile
bva-701 - Drug Profile
onc-301 - Drug Profile
dna Fusion Vaccines - Drug Profile
thyroid Cancer Therapeutics – Drug Profile Updates
thyroid Cancer Therapeutics – Discontinued Products
thyroid Cancer Therapeutics - Dormant Products
thyroid Cancer – Product Development Milestones
featured News & Press Releases
appendix
methodology
coverage
secondary Research
primary Research
expert Panel Validation
contact Us
disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Thyroid Cancer - Pipeline Review, H1 2013

5. Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Thyroid Cancer - Pipeline Review, H1 2013